Skip to main content
. 2021 Jul;25(7):780–784. doi: 10.5005/jp-journals-10071-23863

Table 3.

Treatment options and clinical cure rate

Resistance mechanisms CZA CZA+POL CZA+TIGE CZA+POLY+FOS Total
OXA 48 4/4 3/4 5/7 2/2 14/17
Clinical cure rate 100% 75% 71% 100% 82.35%
CZA+AZT CZA/AZT+POLY CZA+AZT+FOS
NDM +OXA-48 OR NDM 11/12 14/21 6/7 31/40
Clinical cure rate 91.67% 66.67% 85.71% 77.5%